DOI: http://dx.doi.org/10.18203/2349-3933.ijam20213252

Resistant hypertension: a review

Anant Parasher, Rajat Jhamb

Abstract


Resistant hypertension is currently defined as uncontrolled blood pressure despite the use of optimal doses of three antihypertensive medications, of which one is a diuretic. Several factors have been identified as contributors to resistant hypertension such as poor patient adherence, physician inertia, inadequate doses or inappropriate combinations of antihypertensive drugs, excess alcohol intake, certain drugs and volume overload. Uncontrolled blood pressure is a considerable cardiovascular and neurological risk factor that can lead to possible end-organ consequences of untreated hypertension, including heart failure, stroke, ischemic heart disease and renal failure. A comprehensive history and physical examination are essential for pointing towards to an underlying diagnosis. A PubMed search was conducted for review articles and papers from 1955 to 2019 containing the keywords ‘resistant hypertension’, ‘secondary hypertension’, ‘refractory hypertension’, ‘heart failure’ and ‘stroke’, and the literature was compiled. Non-pharmacological measures chiefly include lifestyle modifications such as smoking cessation, reduction in alcohol intake, dietary sodium restriction, healthy eating plans, increased physical activity and weight loss. Among recommended drugs, spironolactone and beta blockers are the preferred fourth- and fifth-line drugs respectively, in patients unresponsive to ACE Inhibitors, calcium channel blockers as well as diuretics. Although most patients are well controlled on extended drug regimes, some develop refractory hypertension which does not even respond to the five-drug regimen. Interventional therapies such as renal denervation and carotid sinus stimulation have been developed for patients with refractory hypertension, but still require further research and follow up to ascertain their full potency and efficacy.


Keywords


Anti-hypertensive, Heart failure, Renal denervation, Resistant Hypertension, Stroke

Full Text:

PDF

References


Williams B, Mancia G, Spiering W. ESC Scientific Document Group. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021-104.

Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ et al. Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/ American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2018;71:2199-269.

Chopra HK, Venkata C, Ram S. Recent Guidelines for Hypertension: A Clarion Call for Blood Pressure Control in India. Circ Res. 2019;124:984-6.

Yaxley JP, Thambar SV. Resistant hypertension: an approach to management in primary care. J Family Med Prim Care. 2015;4(2):193-9.

Faselis C, Doumas M, Vasilios Papademetriou V. Common Secondary Causes of Resistant Hypertension and Rational for Treatment. Int J Hypertens. 2011:236239.

Calhoun DA, Jones D, Textor S. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;117(25):510-26.

Garg JP, Elliott WJ, Folker A, Izhar M, Black HR. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens. 2005; 18(5):619-26.

Papadopoulos DP, Papademetriou v. Resistant hypertension: diagnosis and management. J Cardiovasc Pharmacol Ther. 2006;11(2):113-8.

Sarafidis PA, Bakris GL. Resistant hypertension. An overview of evaluation and treatment. J Am Coll Cardiol. 2008;52(22):1749-57.

Alderman MH. Resistant hypertension: a clinical syndrome in search of a definition. Am J Hypertens. 2008;21(9):965-6.

Moser M, Cushman W, Handler J. Resistant or difficult-to-treat hypertension. J Clin Hypertens. 2006;8(6):434-40.

Amar J. Patients with resistant hypertension. J Hypertens. 2007;25:3-6.

Epstein M. Resistant hypertension: prevalence and evolving concepts. J Clin Hypertens. 2007;9(1):2-6.

Pisoni R, Ahmed I, Calhoun DA. Characterization and treatment of resistant hypertension. Curr Cardiol Rep. 2009;11(6):407-13.

Siddiqui M, Calhoun DA. Refractory versus resistant hypertension. Curr Opin Nephrol Hypertens. 2017;26(1):14-9.

Johnson D. How to treat: Resistant hypertension. Aust Doc. 2007;20:27-34.

Sarafidis PA, Georgianos PI, Zebekakis PE. Comparative epidemiology of resistant hypertension in chronic kidney disease and the general hypertensive population. Semin Nephrol. 2014;34:483-91.

Williams B. Resistant hypertension: an unmet treatment need. Lancet. 2009;374:1396-8.

Moser M, Setaro J. Resistant or Difficult-to-Control Hypertension. N Engl J Med. 2006;355:4.

Persell S. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57:1076-80.

Viera A. Resistant hypertension. J Am Board Fam Med. 2012;25:487-95.

National Heart Foundation and High Blood Pressure Research Council of Australia Ambulatory Blood Pressure Monitoring Consensus Committee. Ambulatory blood pressure monitoring. Aust Fam Phys. 2011;40:877-80.

Canberra: National Heart Foundation of Australia; 2010. National Heart Foundation of Australia. Guide to management of hypertension. 2008.

Rimoldi S, Scherrer U, Messerli F. Secondary arterial hypertension: When, who, and how to screen? Eur Heart J. 2014;35:1245-54.

Halperin JL, Levine GN, Al-Khatib SM, Birtcher KK, Bozkurt B, Brindis RG. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Further Evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classification System. Circulation. 2016;133:1426-8.

Prentice RL. On the ability of blood pressure effects to explain the relation between oral contraceptives and cardiovascular disease. Am J Epidemiol. 1988;127(2):213-9.

Lubianca JN, Faccin CS, Fuchs FD. Oral contraceptives: a risk factor for uncontrolled blood pressure among hypertensive women. Contraception. 2003;67(1):19-24.

Kraiczi H, Peker Y, Caidahl K, Samuelsson A, Hedner J. Blood pressure, cardiac structure and severity of obstructive sleep apnea in a sleep clinic population. J Hypertens. 2001;19(11):2071-8.

Doherty LS, Kiely JL, Swan V, McNicholas WT. Long-term effects of nasal continuous positive airway pressure therapy on cardiovascular outcomes in sleep apnea syndrome. Chest. 2005;127(6):2076-84.

Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet. 2005;365(9464):1046-53.

Conn JW. Presidential address. Part I. Painting background. Part II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1955;45(1):3-17.

White CJ. Catheter-based therapy for atherosclerotic renal artery stenosis. Circulation. 2006; 113(11):1464-73.

Tumelero RT, Duda NT, Tognon AP, Thiesen M. Prevalence of renal artery stenosis in 1,656 patients who have undergone cardiac catheterization. Arquivos Brasileiros de Cardiologia. 2006;87(3):213-53.

Crowley JJ, Santos RM, Peter RH. Progression of renal artery stenosis in patients undergoing cardiac catheterization. Am Heart J. 1998;136(5):913-8.

Leiner T, De Haan MW, Nelemans PJ, Engelshoven JM, Vasbinder GB. Contemporary imaging techniques for the diagnosis of renal artery stenosis. Eur Radiol. 2005;15(11):2219-29.

Cooper CJ, Murphy TP, Matsumoto A. Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. Am Heart J. 2006;152(1):59-66.

Calhoun D, Jones D, Textor S, Goff D, Murphy T, Toto R et al. Resistant hypertension: A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403-19.

London: National Institute for Health and Clinical Excellence. National Institute for Health and Clinical Excellence. Hypertension: Clinical management of primary hypertension in adults. 2011.

Frank J. Managing hypertension using combination therapy. Am Fam Phys. 2008;77:1279-86.

Kaplan N. The choice of thiazide diuretics: Why chlorthalidone may replace hydrochlorothiazide. Hypertension. 2009;54:951.

Kumar N, Calhoun D, Dudenbostel T. Management of patients with resistant hypertension: Current treatment options. Integr Blood Press Control. 2013;6:139-51.

eTG complete. 2015. Available at: www.online.tg.org.au. Accessed on 2014 Feb 15.

Madkour H, Gadallah M, Riveline B, Plante GE, Massry SG. Indapamide is superior to thiazide in the preservation of renal function in patients with renal insufficiency and systemic hypertension. Am J Cardiol. 1996;77:23-5.

Chapman N, Dobson J, Wilson S, Dahlhoef B, Sever P, Wedel H et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839.

Myat A, Redwood S, Qureshi A, Spertus J, Williams B. Resistant Hypertension. BMJ. 2012;345:e7473.

Black H, Elliot W, Grandits G, Grambasch P, Lucente T, White W, et al. Principal results of the Controlled Onset Investigation of Cardiovascular Endpoints (CONVINCE) Trial. JAMA. 2003;289:2073.

Coppolino G, Pisano A, Rivoli L, Bolignano D. Renal denervation for resistant hypertension. Cochrane Database Syst Rev. 2017;2(2):CD011499.

Witkowski A, Prejbisz A, Florczak E, Kadziela J, Sliwinski P, Bielen P et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58:559‐65.

Zhang J, Zhou S, Xu G. Carotid baroreceptor stimulation: a potential solution for resistant hypertension. Interv Neurol. 2014;2(3):118-22.

Thrasher TN. Unloading arterial baroreceptors causes neurogenic hypertension. Am J Physiol Regul Integr Comp Physiol. 2002;282:1044-53.

Papademetriou V, Doumas M, Faselis C, Tsioufis C, Douma S, Gkaliagkousi E et al. Carotid baroreceptor stimulation for the treatment of resistant hypertension. Int J Hypertens. 2011;2011:964394.

Thrasher TN. Baroreceptors and the long‐term control of blood pressure. Exp Physiol. 2004;89:331-5.

Tordoir J, Scheffers I, Schmidli J, Savolainen H, Liebeskind U, Hansky B et al. An implantable carotid sinus baroreflex activating system: surgical technique and short-term outcome from a multi-center feasibility trial for the treatment of resistant hypertension. Eur J Vasc Endovasc Surg. 2007;33:414-21.